In summary, our systems biology approach that integrates multimodal omics and phenotype data across species with experimental validations discovered DDR2, STOM and KANK2 as potential therapeutic targets in PSP. This evidence concerns the gene KANK2 and supranuclear palsy, progressive, 1.